Fig. 1

Flowchart showing the process used for study selection. Thirty patients were enrolled, all with tumor and liquid biopsies at enrollment. A total of five patients were excluded: three had adverse events, one was unwilling to participate, and one died shortly after starting. Eighteen patients underwent an interim liquid biopsy. After the interim liquid biopsy, seven patients were also excluded: three did not reach PD, three had adverse events, and one was unwilling to participate. Finally, 18 patients reached PD, of whom 18 had liquid biopsy and 10 had tumor re-biopsy. PD, progressive disease